rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GERN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Geron Targets Germany Launch and Deals as RYTELO Sales Grow
      Nov 11Yahoo FinanceGERN
      Geron at Stifel 2026 Healthcare Conference: RYTELO gains traction
      Nov 10Investing.comGERN
      What Investors Got Wrong About Geron Before The Drop
      Nov 8Yahoo FinanceGERN
      Geron: 3 Key Takeaways for Long-Term Investors
      Nov 5Yahoo FinanceGERN
      Geron Corp (GERN) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 5The Globe and MailGERN
      Geron Corp (GERN) Q3 2026 Earnings Call Highlights: RYTELO Revenue Climbs 27% as Cost Cuts Lift ...

      Geron Corp (GERN) posted $60.1 million in quarterly RYTELO revenue and trimmed its 2026 operating expense outlook, even as it discontinued its Phase III IMpactMF myelofibrosis trial.

      Nov 4Yahoo FinanceGERN
      Geron Corporation Q3 2026 Earnings Call Summary
      Nov 4Yahoo FinanceGERN
      Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
      Nov 4Yahoo FinanceGERN
      Geron Q3 2026 Earnings Call Transcript
      Nov 4BenzingaGERN
      Earnings call transcript: Geron Q3 2026 revenue rises 27% as stock gains premarket
      Nov 4Investing.comGERN
      Geron stock gains after Q3 2026 results (GERN:NASDAQ)
      Nov 4Seeking AlphaGERN
      Geron (GERN) Reports Break-Even Earnings for Q3
      Nov 4Yahoo FinanceGERN
      Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Nov 4Yahoo FinanceGERN
      Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
      Nov 3Yahoo FinanceGERNSF
      Geron: Opportunity Builds Even As Struggles Continue (NASDAQ:GERN)
      Nov 2Seeking AlphaGERN
      Geron Corporation: IMPACT-MF Study Discontinuation May Not Be So Disastrous (NASDAQ:GERN)

      With the MF label expansion closed, Geron Corporation will focus on maximizing Rytelo's approved lower-risk MDS indication. I rate the GERN stock as Hold. Click to know more.

      Oct 29Seeking AlphaGERN
      Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
      Oct 28BenzingaGERN
      Geron's Core Rytelo Business Remains on Track Despite Trial Halt, Wedbush Says
      Oct 28Yahoo FinanceGERN
      Wedbush cuts Geron stock price target to $5 on study halt
      Oct 28Investing.comGERN
      Geron stock drops after halting Rytelo trial (GERN:NASDAQ)

      Geron (GERN) stock falls as the company halts a late-stage trial for its blood cancer therapy imetelstat, marketed as Rytelo. Read more here.

      Oct 28Seeking AlphaGERN
      Geron stock tumbles after halting Phase 3 trial
      Oct 28Investing.comGERN
      Why is Geron stock sliding today?
      Oct 28Investing.comGERN
      Geron discontinues phase 3 myelofibrosis trial on survival concerns
      Oct 28Investing.comGERN
      Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
      Oct 28Yahoo FinanceGERN
      Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
      Oct 21Yahoo FinanceGERN
      Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 19Yahoo FinanceGERN
      Geron Corporation Rings the Closing Bell

      About This EventGeron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, visits the Nasdaq MarketSite in Times Square to commemorate 30 years of being listed on Nasdaq. In honor of the occasion, Harout Semerjian, President and Chief Executive Officer, rings the Closing Bell.

      Oct 16NasdaqGERN
      Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

      Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndrome

      Oct 12Yahoo FinanceGERN
      Geron Q2 2026 Earnings Call: Complete Transcript - Geron (NASDAQ:GERN)

      Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire

      Oct 8BenzingaGERN
      Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

      Detailed price information for Fair Isaac and Company (FICO-N) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailGERNFICO
      Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 18Yahoo FinanceGERN
      Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

      Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $

      Sep 16Yahoo FinanceGERN
      Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

      Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur

      Sep 13Yahoo FinanceGERN
      Geron at cantor healthcare conference: RYTELO growth, profit path
      Sep 9Investing.comGERN
      Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
      Sep 2MorningstarGERN
      Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
      Sep 2MorningstarGERN
      Geron to Present at Upcoming Investor Conferences

      FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen

      Sep 2Yahoo FinanceGERN

      This is the newest page. Registered accounts read further back.